AMD-070 Hydrochloride: Potent and Selective CXCR4 Antagonist for Anti-HIV and Genomic Research

Executive Summary: AMD-070 hydrochloride is a high-purity small molecule antagonist of the CXCR4 chemokine receptor, widely used in anti-HIV drug development and CXCR4 signaling research (APExBIO). It exhibits a molecular weight of 458.86 Da and solubility ≥45.9 mg/mL in water, enabling robust experimental design. AMD-070 hydrochloride blocks HIV entry by inhibiting CXCR4-CXCL12 interactions, a validated therapeutic target in hematologic malignancies and viral pathogenesis (Sarosiek et al., 2021). Its performance benchmarks have been established in cell assay systems and genomic profiling contexts. The compound is for research use only, not for diagnostic or clinical application.

Biological Rationale

CXCR4 is a G protein-coupled chemokine receptor expressed on hematopoietic and immune cells. The receptor binds CXCL12 (also called SDF-1α), mediating cell migration, homing, and survival. CXCR4 is implicated in HIV infection, cancer metastasis, and hematologic malignancies (Sarosiek et al., 2021). Somatic mutations in CXCR4 are present in 30–40% of Waldenström macroglobulinemia (WM) patients, influencing treatment selection and prognosis. In HIV, CXCR4 acts as a co-receptor for viral entry into host cells. Inhibiting CXCR4 disrupts these pathological processes, making antagonists like AMD-070 hydrochloride valuable research tools (see related).

Mechanism of Action of AMD-070 hydrochloride

AMD-070 hydrochloride is a small molecule that binds the CXCR4 receptor with high affinity, preventing its interaction with CXCL12. This blockade inhibits downstream signaling cascades such as PI3K/AKT and MAPK/ERK, which are critical for cell migration and survival. In HIV research, AMD-070 hydrochloride interferes with viral gp120 binding to CXCR4, blocking entry of X4-tropic HIV-1 strains into CD4+ T-cells. The compound is cell-permeable and active in both in vitro and ex vivo models (contrast: deeper MOA).

Evidence & Benchmarks

• AMD-070 hydrochloride demonstrates nanomolar potency (IC₅₀ ~13 nM) in inhibiting CXCL12-induced chemotaxis in human cell lines (Sarosiek et al., 2021).
• It effectively blocks HIV-1 entry into CD4+ T-cells by targeting CXCR4, with high selectivity over CCR5 (Sarosiek et al., 2021).
• AMD-070 hydrochloride is ≥98% pure and highly soluble (≥45.9 mg/mL in water), ensuring robust and reproducible assay conditions (APExBIO).
• Long-term storage of prepared solutions is not recommended; freshly prepared solutions maintain compound stability and activity (APExBIO).
• Genomic profiling studies in WM highlight the clinical impact of CXCR4 antagonism in cases with CXCR4 mutations, supporting the rationale for research applications (Sarosiek et al., 2021).

Applications, Limits & Misconceptions

AMD-070 hydrochloride is used for:

• Studying CXCR4 signaling in cell migration, survival, and proliferation assays (update: broader HIV focus).
• Evaluating HIV entry inhibition in anti-HIV research and drug screening.
• Investigating CXCR4 function in models of hematologic malignancies, including WM.
• Facilitating genomic correlation studies between CXCR4 mutation status and compound response (extends: genomic insights).

Common Pitfalls or Misconceptions

• AMD-070 hydrochloride is not a CCR5 antagonist and will not block CCR5-mediated HIV entry.
• It is intended for research use only; not for diagnostic or clinical therapeutic applications.
• Inactive against CXCR4-independent migration pathways; alternative mechanisms must be excluded.
• Long-term storage of dissolved compound (>7 days) may lead to reduced efficacy; always prepare fresh solutions.
• Does not reverse established HIV infection; effective primarily at the entry inhibition stage.

Workflow Integration & Parameters

AMD-070 hydrochloride is supplied as a brown oil (SKU A3174) by APExBIO (product page). The recommended storage is at -20°C. The compound is highly soluble in water (≥45.9 mg/mL), DMSO (≥33.33 mg/mL), and other aqueous buffers. For cell culture or biochemical assays, dissolve immediately before use. Typical working concentrations range from 1 nM to 10 μM, depending on cell type and assay conditions. Purity is ≥98%. Experimental protocols should include appropriate CXCR4-dependent controls and replicate measurements. For guidance on troubleshooting cytotoxicity or assay compatibility, see this article (clarifies workflow challenges compared to this comprehensive overview).

Conclusion & Outlook

AMD-070 hydrochloride remains a benchmark tool for dissecting CXCR4-mediated processes in anti-HIV and cancer research. Its potency, selectivity, and robust solubility profile underpin its widespread adoption in academic and translational studies. Ongoing research leveraging compounds like AMD-070 hydrochloride is expected to clarify the complex role of CXCR4 in viral entry and hematologic malignancy pathogenesis, and guide future therapeutic strategies (Sarosiek et al., 2021).